吉非替尼一线治疗局部晚期或转移性非小细胞肺癌的临床观察

目的：评价吉非替尼一线治疗局部晚期或转移性非小细胞肺癌（ＮＳＣＬＣ）的疗效和安全性。方法：４５例局部晚期或转移性ＮＳＣＬＣ一线应用吉非替尼２５０ｍｇ／ｄ，直至出现肿瘤进展或不可耐受的毒副反应。结果：４５例可评价病例中，无完全缓解（ＣＲ），部分缓解（ＰＲ）１５例，病情稳定（ＳＤ）１７例，疾病进展（ＰＤ）１３例。全组有效率为３３.３％，疾病控制率为７１.１％。疾病相关症状缓解率为７２.５％，中位缓解时间为８天。中位生存期１５.３个月，中位无进展生存期为６.０个月。主要的毒副作用为皮疹２４例（５３.３％），腹泻１５例（３３.３％），皮肤干燥脱屑１２例（２６.７％），皮肤瘙痒１０例（２２.２％），恶性呕吐８例（１７.８％），转氨酶升高３例（６.７％）及口腔溃疡２例（４.４％）。结论：吉非替尼一线治疗局部晚期或转移性ＮＳＣＬＣ有较好的疗效和安全性。

Clinical observation of gefitinib as the first line therapy for advanced or metastatic non-small cell lung cancer

Objective：To evaluate the activity and toxicities of gefitinib as the first line therapy for advanced or metastatic non-small cell lung cancer（NSCLC）. Methods ： Forty-five patients with advanced or metastatic NSCLC were treated with gefitinib 250mg p. o. once daily until disease progression or unacceptable toxicities. Results：No patient showed complete response and 15 patients showed partial response making the overall response rate 33.3%. Seventeen patients showed stable disease, so disease control rate was 71.1%. Thirteen patients showed disease progression. Remission rate of disease-related symptoms was 72. 5%. The median remission time was eighth day. Median time to progression was 6.0 months and median overall survival time was 15.3 months. The main toxicities were rash （53.3%）, diarrhea（ 33.3% ）, ect. There was no treatment-related deaths. Conclusion ： Gefitinib as the first line therapy for advanced or metastatic NSCLC was effective and security.